- Home
- JRS vs GALT Comparison
JRS vs GALT Comparison
Compare JRS & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$2.30
Company Overview
Basic Information| Metric | JRS | GALT |
|---|---|---|
| Founded | 2001 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.9M | 199.2M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | JRS | GALT |
|---|---|---|
| Price | $7.90 | $2.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 78.3K | ★ 340.4K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 8.87% | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.12 | $1.22 |
| 52 Week High | $8.38 | $7.13 |
Technical Indicators
Market Signals| Indicator | JRS | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 60.35 | 37.18 |
| Support Level | $7.56 | $2.07 |
| Resistance Level | $7.89 | $3.32 |
| Average True Range (ATR) | 0.16 | 0.21 |
| MACD | 0.07 | -0.04 |
| Stochastic Oscillator | 90.52 | 13.69 |
Price Performance
Historical Comparison JRS
GALT
About JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.